Preclinical News and Research

RSS

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.

19 Jul 2013

HemoShear announces milestone in development of predictive drug safety systems

HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals.

19 Jul 2013

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

Heart tissue sustains irreparable damage in the wake of a heart attack. Because cells in the heart cannot multiply and the cardiac muscle contains few stem cells, the tissue is unable to repair itself - it becomes fibrotic and cannot contract properly.

18 Jul 2013

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems.

17 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Study identifies new therapeutic targets for Huntington's disease

A scientific study describes that GluN3A subunits of NMDA receptors that interact with glutamate —the main exciting neurotransmitter in the nervous system— are therapeutic targets against Huntington's disease.

16 Jul 2013

Alize Pharma initiates AZP-531 Phase I clinical trial for treatment of type 2 diabetes

Alize Pharma, a company specialized in the development of drugs for the treatment of metabolic diseases and rare diseases, announces today the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.

16 Jul 2013

Ipsen closes acquisition of UK-based Syntaxin

Ipsen announced today the closing of the acquisition of Syntaxin, a UK-based private life sciences company specialized in botulinum toxin engineering.

15 Jul 2013

C2N Diagnostics, CIL sign collaborative research and global supplier agreement

C2N Diagnostics today announced that it has signed a collaborative research and a global, exclusive supplier agreement with Cambridge Isotope Laboratories, Inc. The partnership guarantees C2N's future access to mass quantities of highly enriched stable isotopes at predictable prices.

12 Jul 2013

International team explores genetic diversity of Plasmodium vivax in the Americas

Human migrations - from the prehistoric epoch to the present day - have extended cultures across the globe. With these travelers have come unwanted stowaways: mosquito-borne parasites belonging to the Plasmodium species - a group responsible for malaria, worldwide.

12 Jul 2013

Antibodies boost immune system to fight childhood cancer, shows study

Researchers in the Antibody and Vaccine Group have developed two monoclonal antibodies (mAbs) called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4. Each of these antibodies binds to a different target molecule in the immune system, potentially heightening the body's own immune response to cancer.

12 Jul 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

A recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

12 Jul 2013

Heart transplant could get a second chance to save life

Human hearts which are not used each year because they are deemed unsuitable for an organ transplant could get a second chance to save a life, with the help of new research taking place in the North East.

11 Jul 2013

Immunocore, GSK partner for cancer targeting ImmTACs

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

10 Jul 2013

Research: Boosting levels of gut hormones may be effective weapon in fight against obesity

In the constant cross talk between our brain and our gut, two gut hormones are already known to tell the brain when we have had enough to eat. New research suggests that boosting levels of these hormones simultaneously may be an effective new weapon in the fight against obesity.

10 Jul 2013

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

NextBio, whose Big Data technology enables users to apply genomic data from disparate sources in novel and useful ways across life sciences research, today announced that Boehringer Ingelheim has signed a multi-year renewal agreement to the NextBio Research Platform.

9 Jul 2013

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

The politicians' consensus is that health care reform shouldn't alter or disrupt the way the majority of Americans get their insurance today. ... The policy consensus, though, is that the status quo is actually the problem, and that it deserves to be threatened, undermined and replaced as expeditiously as possible. Wonks of the left and right disagree on what that replacement should look like. But they're united in regarding employer-provided coverage as an unsustainable relic (Ross Douthat, 7/6).

9 Jul 2013

Preclinical News and Research

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

HemoShear announces milestone in development of predictive drug safety systems

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Gold nanofibers in engineered heart tissue can enhance electrical signalling, find researchers

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Study identifies new therapeutic targets for Huntington's disease

Alize Pharma initiates AZP-531 Phase I clinical trial for treatment of type 2 diabetes

Ipsen closes acquisition of UK-based Syntaxin

C2N Diagnostics, CIL sign collaborative research and global supplier agreement

International team explores genetic diversity of Plasmodium vivax in the Americas

Antibodies boost immune system to fight childhood cancer, shows study

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

Heart transplant could get a second chance to save life

Immunocore, GSK partner for cancer targeting ImmTACs

Research: Boosting levels of gut hormones may be effective weapon in fight against obesity

Boehringer Ingelheim signs multi-year renewal agreement to NextBio Research Platform

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics